{"groups":[{"description":"Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR.","id":"FG000","title":"Gemcitabine and Paclitaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"42"}],"type":"Progression/relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never received treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"67"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"Eligible and Began Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}